{"id":"57e3aa6e-0415-5442-8a9b-9a786567b4b3","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-iv-tolerability","predicate":"associated_with","statement":"A retrospective commercial-clinic series compared six clients receiving 500 mg IV NAD+ with eight receiving 500 mg IV NR over four-day loading protocols; NAD recipients reported gastrointestinal symptoms, chest pressure or elevated heart rate and required longer infusions.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"4d786cdd-2c86-53db-b031-f7908ab09117","mechanism_event_label":"Infusion tolerability is a separate question from whether NAD biomarkers rise.","subject":{"id":"35010247-8e1e-5ea0-ab54-f32b9956f825","slug":"human-intravenous-nad-intervention","display_name":"Intravenous NAD+ intervention in humans","entity_type_key":"cellular_process"},"object":{"id":"aed3555a-b245-5bbc-8f43-f9720f47b79b","slug":"human-iv-nad-infusion-symptoms","display_name":"Symptoms during commercial IV NAD infusions","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4d786cdd-2c86-53db-b031-f7908ab09117","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-iv-tolerability-event","event_type":"observed_relationship","label":"Infusion tolerability is a separate question from whether NAD biomarkers rise.","description":"A retrospective commercial-clinic series compared six clients receiving 500 mg IV NAD+ with eight receiving 500 mg IV NR over four-day loading protocols; NAD recipients reported gastrointestinal symptoms, chest pressure or elevated heart rate and required longer infusions.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"35010247-8e1e-5ea0-ab54-f32b9956f825","slug":"human-intravenous-nad-intervention","display_name":"Intravenous NAD+ intervention in humans","entity_type_key":"cellular_process"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"aed3555a-b245-5bbc-8f43-f9720f47b79b","slug":"human-iv-nad-infusion-symptoms","display_name":"Symptoms during commercial IV NAD infusions","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Small nonrandomized retrospective clinical series.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Selection, infusion rate and clinic practices limit causal comparison; not efficacy evidence or an incidence estimate for all users.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Infusion tolerability is a separate question from whether NAD biomarkers rise.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41704678/ · DOI 10.3389/fragi.2026.1652582","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"678cdf5c-fb2d-5410-8d53-72149ba19497","evidence_kind":"source_excerpt","locator":"Lines 300-306","start_line":300,"end_line":306,"excerpt":"## nad-plus-iv-tolerability\nInfusion tolerability is a separate question from whether NAD biomarkers rise.\nA retrospective commercial-clinic series compared six clients receiving 500 mg IV NAD+ with eight receiving 500 mg IV NR over four-day loading protocols; NAD recipients reported gastrointestinal symptoms, chest pressure or elevated heart rate and required longer infusions.\nModel: Small nonrandomized retrospective clinical series.\nLimitations: Selection, infusion rate and clinic practices limit causal comparison; not efficacy evidence or an incidence estimate for all users.\nEvidence access: Primary full text\nIntravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41704678/ · DOI 10.3389/fragi.2026.1652582","model_system":"Small nonrandomized retrospective clinical series.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"f59aa302-d463-5462-876f-e21e64861eac","stable_key":"import-8c946991-97f0-55ee-8df0-00e67621962f","title":"NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"9f5324d0d652c80ad630b3100e28ce34cd2ce260ea2e1324332a4262ce72ae09","revision_id":"0e07909c-e8bc-5950-bafc-61371d9d6412","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}